Artificial intelligence is making it easier than ever to create things in medical technology.
That should make us nervous.
Today, an algorithm can generate a device concept, analyze a market, draft a patent, simulate performance, design a clinical trial, and produce an investor presentation before anyone has spoken to a patient. The modern MedTech entrepreneur can move from idea to company with astonishing speed.
But speed is not wisdom. And innovation is not progress simply because it arrives quickly.
Medicine is becoming increasingly vulnerable to technological theatre: impressive software, elaborate robotics, intelligent dashboards, and devices that photograph well at conferences but solve problems clinicians never considered urgent. We have begun to confuse sophistication with value. A technology is called disruptive because it uses artificial intelligence, not because it meaningfully improves a patient’s life.
The uncomfortable truth is that some medical innovation exists primarily because it can attract capital.
The patient becomes a supporting character in a story written for investors. Clinical problems are enlarged to justify markets. Marginal improvements are described as revolutions. Complexity is added because complexity can be patented, priced, and promoted.
Meanwhile, the person lying on the operating table does not care whether the device uses artificial intelligence. They care whether it works. For example, endovascular techniques have transformed surgery by allowing us to treat disease from within the blood vessels, often through a small puncture rather than a large incision. But the elegance of the approach can disguise the brutality of the underlying reality. These patients may be bleeding, ischemic, unstable, or out of options.
In those moments, technology is stripped of its marketing language.
It is either useful or it is not.
AI can help us design faster, test more possibilities, identify patterns, and challenge assumptions. It may become one of the most powerful tools ever available to physician-inventors and engineers. But AI has no experience of illness. It has never watched a patient deteriorate. It has never felt the weight of a complication or explained a death to a family.
It can optimize a device. It cannot decide what we owe the patient.
That remains a human responsibility.
The future of MedTech should not be defined by how much intelligence we can put inside a machine. It should be defined by how much suffering we can remove from medicine. Sometimes that will require advanced algorithms and robotics. Sometimes it will require a smaller catheter, a simpler design, or a tool that can be used in a hospital without extraordinary infrastructure.
True innovation may be less impressive than technological theatre. It may be quiet, practical, and almost obvious once it exists.
Perhaps the most dangerous question in the age of AI is, “What can we build?”
A wiser question is, “What is worth building?”
The difference between those questions is the difference between invention and responsibility. AI will make invention faster. It will not make responsibility easier.
